Mark Bachleda
Geen lopende functies
Vermogen: 2 277 $ op 30-04-2024
Loopbaan van Mark Bachleda
Eerdere bekende functies van Mark Bachleda
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| GALERA THERAPEUTICS, INC. | Corporate Officer/Principal | 12-10-2021 | 09-08-2023 |
| JUNO THERAPEUTICS INC | Verkoop & Marketing | - | - |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | - | - |
Opleiding van Mark Bachleda
| University of Illinois | Doctorate Degree |
| University of California, Berkeley | Masters Business Admin |
Statistieken
Internationaal
| Verenigde Staten | 6 |
Operationeel
| Corporate Officer/Principal | 2 |
| Doctorate Degree | 1 |
| Masters Business Admin | 1 |
Sectoraal
| Health Technology | 4 |
| Consumer Services | 3 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| GALERA THERAPEUTICS, INC. | Health Technology |
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Juno Therapeutics, Inc.
 Juno Therapeutics, Inc. BiotechnologyHealth Technology Juno Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of innovative cellular immunotherapy for the treatment of cancer. It offers platforms which includes chimeric antigen receptors and T-cell receptors. The company was founded by Hans Edgar Bishop, Lawrence Corey, Richard D. Klausner, Stan Riddell, Isabelle Riviere, and Robert Taylor Nelsen on August 5, 2013 and is headquartered in Seattle, WA. | Health Technology |
- Beurs
- Insiders
- Mark Bachleda
- Ervaring